Lupic Outbreak and Covid-19 Pneumonia-Case Report

2021 ◽  
Vol 7 (5) ◽  
pp. 01-06
Author(s):  
Tamayo Luis
Keyword(s):  
Case Report ◽  
Autoimmune Disease ◽  
Respiratory Infection ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systematic Lupus Erythematosus ◽  
Population Groups ◽  
Therapeutic Challenge ◽  
Pneumonia Case ◽  
Lupus Flare

Coronavirus disease 2019 (COVID-19) is a respiratory infection that can cause mild symptoms or even death, to patients who suffer from it. It affects all population groups without distinction. Systematic Lupus Erythematosus (SLE) is a chronic and fluctuating autoimmune disease. One of the goals of the treatment is to avoid flare-ups and thereby reduce mortality. Their innate alterations in immunity, added to the use of immunosuppressive drugs to control the disease and prevent outbreaks makes them more vulnerable to develop severe symptoms in SARS-CoV-2 infection. We present the case of a patient with SLE infected by SARS-CoV-2 with a lupus flare during hospitalization, entailing a diagnostic and therapeutic challenge.

scholarly journals Drug-Induced Gingival Overgrowth in an 8-Year-Old Girl: A Case Report

2021 ◽  
Vol 13 (3) ◽  
pp. 109-112
Author(s):  
Parviz Torkzaban ◽  
Amir Talaie
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Immunological Tolerance ◽  
Systemic Autoimmune Disease ◽  
Channel Blockers ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Gingival Overgrowth

Systemic lupus erythematosus is a systemic autoimmune disease that involves multi organs. Genetic, endocrine, immunological, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The gingival overgrowth can be caused by three factors: noninflammatory, hyperplastic reaction to the medication; chronic inflammatory hyperplasia; or a combined enlargement due to chronic inflammation and drug-induced hyperplasia. Drug-Induced Gingival Overgrowth is associated with the use of three major classes of drugs, namely anticonvulsants, calcium channel blockers, and immunosuppressants. Due to recent indications for these drugs, their use continues to grow.

scholarly journals Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Ryusuke Yoshimi ◽  
Yoshiaki Ishigatsubo ◽  
Keiko Ozato
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systemic Autoimmune Disease ◽  
Type I ◽  
Systemic Lupus ◽  
Molecular Features ◽  
Attractive Therapeutic Target ◽  
Autoimmune Processes

Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines. In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE.

scholarly journals Vesiculobollous disease with Cutaneous Systemic Lupus Erythematosus Treated by Rituxima; a case report

2021 ◽  
Author(s):  
Wigdan Mohammed Niamat Alla ◽  
Burhan Mohamed Ali Ahmed ◽  
Mohammed Elmujtba Adam Essa ◽  
Atif Elhadi Abdalla Babker ◽  
Elnour Mohammed Elagib
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Chronic Autoimmune Disease

SLE is a chronic autoimmune disease characterized by multisystem inflammation, Vesiculobullous (VB) are different groups of oral disorders characterized by the formation of bullae. The aim of this report is to describe a case of a vesiculobullous disease in SLE.

scholarly journals Pulmonary tuberculosis in a patient with rheumatoid arthritis undergoig immunosuppressive treatment: case report

2014 ◽  
Vol 47 (1) ◽  
pp. 60-62 ◽  
Author(s):  
Sandro Ceratti ◽  
Talita Rombaldi Pereira ◽  
Sílvio Fontana Velludo ◽  
Leonardo Pereira Dalcim ◽  
Gladston Oliveira Machado ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Autoimmune Disease ◽  
Pulmonary Tuberculosis ◽  
Opportunistic Infections ◽  
Immunosuppressive Treatment ◽  
Immunosuppressive Drugs ◽  
Present Case Report

Rheumatoid arthritis is a disease which characteristically affects the joints. Because it is an autoimmune disease, immunosuppressive drugs are widely used in its treatment. The present case report illustrates the association of immunosuppressive treatment with the development of opportunistic infections in a 64-year-old patient.

scholarly journals Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus

2021 ◽  
Vol 12 ◽  
Author(s):  
Sean Robinson ◽  
Ranjeny Thomas
Keyword(s):  
Lupus Erythematosus ◽  
Survival Rates ◽  
Clinical Manifestations ◽  
Treg Cells ◽  
Immunological Tolerance ◽  
Immunosuppressive Drugs ◽  
Systemic Autoimmune Disease ◽  
Systematic Lupus Erythematosus ◽  
Curative Therapy

Systemic lupus erythematosus (SLE) is a chronic complex systemic autoimmune disease characterized by multiple autoantibodies and clinical manifestations, with the potential to affect nearly every organ. SLE treatments, including corticosteroids and immunosuppressive drugs, have greatly increased survival rates, but there is no curative therapy and SLE management is limited by drug complications and toxicities. There is an obvious clinical need for safe, effective SLE treatments. A promising treatment avenue is to restore immunological tolerance to reduce inflammatory clinical manifestations of SLE. Indeed, recent clinical trials of low-dose IL-2 supplementation in SLE patients showed that in vivo expansion of regulatory T cells (Treg cells) is associated with dramatic but transient improvement in SLE disease markers and clinical manifestations. However, the Treg cells that expanded were short-lived and unstable. Alternatively, antigen-specific tolerance (ASIT) approaches that establish long-lived immunological tolerance could be deployed in the context of SLE. In this review, we discuss the potential benefits and challenges of nanoparticle ASIT approaches to induce prolonged immunological tolerance in SLE.

scholarly journals Chorea in systematic lupus erythematosus ; a case report

2013 ◽  
Vol 36 (6) ◽  
pp. 467-472 ◽  
Author(s):  
Yo UEDA ◽  
Yuko TAKAHASHI ◽  
Hiroyuki YAMASHITA ◽  
Tosikazu KANO ◽  
Akio MIMORI
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Systematic Lupus Erythematosus

scholarly journals Elderly-onset systematic lupus erythematosus in men. Case Report

2011 ◽  
Vol 0 (3) ◽  
pp. 89
Author(s):  
Nataliya Valeryev Seredavkina ◽  
T M Reshetnya ◽  
S G Radenska-Lopovok
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Systematic Lupus Erythematosus ◽  
Elderly Onset
Sign in / Sign up

Export Citation Format

Share Document